17 Aug Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Pradaxa
Posted at 12:52h
in
Notification of an important new warning with treatment of patients with anti phospholipid syndrome (APS) and the use Pradaxa: Increased risk of thrombo-embolic events
2019 Aug
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
16/08/2019
File Type:
pdf
Category:
Communication To Health Care Professionals